Recent advances in epidemiology, prevention and treatment of hepatitis B in China
10.3760/cma.j.cn501113-20250127-00046
- VernacularTitle:中国乙型肝炎最新流行病学及防治进展
- Author:
You DENG
1
;
Tongtong MENG
;
Hong YOU
;
Yu WANG
;
Jidong JIA
Author Information
1. 首都医科大学附属北京友谊医院肝病中心 国家消化系统疾病临床研究中心 消化健康国家重点实验室，北京 100050
- Publication Type:Journal Article
- Keywords:
Chronic Hepatitis B;
Epidemiology;
Treatment;
Functional cure;
Public health intervention
- From:
Chinese Journal of Hepatology
2025;33(2):115-120
- CountryChina
- Language:Chinese
-
Abstract:
China has made remarkable achievements during the past three decades in controlling chronic hepatitis B virus infection. The overall HBsAg positivity rate dropped from 9.72% in 1992 to 5.86% in 2020. Particularly, the HBsAg positivity rate among children under five years old has dropped from 9.67% in 1992 to 0.30% in 2020. This transition is due to the universal vaccination of newborns with hepatitis B vaccine since 1992, which has averted over 40 million of HBV infections and seven million hepatitis B-related deaths. However, there are still around 75 million cases of chronic hepatitis B virus infection in China, of which about 59.78% of the infected individuals were aware of their infection status before survey, and about 30 million people have not yet been diagnosed. Among the confirmed infected individuals, 38.25% (about 17 million people) have indications for antiviral treatment, but only 17.33% (about 3 million people) are receiving antiviral treatment. Therefore, in order to accelerate the actualization of the World Health Organization's goal of eliminating viral hepatitis as a public health threat by 2030, China has taken a series of active measures in recent years, including updating clinical guidelines and expanding treatment indications to improve the coverage of diagnosis and treatment. At the same time, Chinese pharmaceutical companies and academia have made significant progress in the research and development of innovative hepatitis B therapies, laying the foundation for achieving the functional cure of chronic hepatitis B. Furthermore, China has developed a comprehensive management model for the prevention, control, and elimination of hepatitis B through evidence-based public health interventions, optimized clinical management strategies, and promotion of innovative drugs, providing valuable experience for the world.
